Cox-2 Inhibitors Compared with Opioids

Because they are in the same family of medication, all Cox-2 inhibitors behave in pretty much the same way. Therefore, patients who replace Vioxx or Bextra with Celebrex may still be at risk for heart attacks. Although they are not Cox-2 inhibitors, other NSAIDs that pose potential dangers are Motrin, Naprosyn, Voltaren and Mobic.

Opioids are very strong pain relievers; morphine is the best known example of opioids, although there are actually several types ranging from mild-acting to very strong. Examples include OxyContin, codeine, Darvon and Vicodin.

Opioids have several side effects, including the possibility of:

• respiratory depression
• constipation
• risk of dependancy and addiction

The most obvious disadvantage of opioids as pain medication is the potential for addiction and dependency. Research indicates that OxyContin, in particular, is a "gateway" to addiction to other hard drugs. Sometimes, patients may be denied the medication because their motivations are misunderstood, and they may be seen as potential morphine (or other opioid) addicts.

When properly administered, the benefits of taking opioids for pain are stronger than the associated risks. Opioids are quite effective for pain relief. And many researchers, governing bodies in medicine, and doctors feel that opioids are worth considering for the treatment of chronic pain. But as with any health care choice, work with your doctor and other healthcare professionals to find the best option for you.

_{Source:
Questions and Answers.FDA Regulatory Actions for the COX-2 Selective and Non-Selective Non-Steroidal Anti-inflammatory drugs (NSAIDs). FDA. April 7, 2005.
Brasseur, L. Review of current pharmacologic treatment of pain. Drugs. 1997.
Cicero, T.J., Inciardi, J.A., Munoz, A. Trends in abuse of Oxycontin and other opioid analgesics in the United States 2002-2004 JPain Oct. 2005.
Grau, L.E., Dasgupta, N., Harvey, A.P., Irwin, K., Givens, A., Kinzley, M.L., Heimer, R.. Illicit use of opioids: is OxyContin a "gateway" drug? AmJ Addict May-June 2007.}